Summary
Live60 webinars are sixty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
To commercialize AAV-based gene therapies for cardiometabolic and age-related disease treatment, developers must adopt novel technologies that optimize viral vector manufacturing by improving yield, packaging efficiency, and contaminant-free scalability.
In April, Rejuvenate Bio’s Dan Oliver (CEO, Co-Founder) and Advanced Therapies’ Ji Hyun “Jackie” Lee (Process Development Scientist) will present data on therapeutic pipeline breakthroughs, innovative technologies, and clinical and manufacturing strategies designed to transform the treatment of chronic diseases via AAV-based gene therapies.
- Learn how single-administration AAV gene therapies can effectively and profitably address cardiometabolic and age-related diseases
- Gain insights into the pipeline breakthroughs in human and animal health, including RJB-0402 for cardiac and metabolic conditions, as well as RJB-01 and RJB-02 for serious diseases in dogs
Explore an advanced AAV manufacturing platform that optimizes viral vector manufacturing by improving yield, packaging efficiency, and contaminant-free scalability.